NCT01238679 is a Phase 1 clinical trial of PF-04958242 in Healthy Volunteers, sponsored by Biogen.

Who is sponsoring NCT01238679?

NCT01238679 is sponsored by Biogen.

What drugs are being tested in NCT01238679?

Interventions in NCT01238679: PF-04958242, Placebo.

What condition does NCT01238679 study?

NCT01238679 studies Healthy Volunteers.

Is NCT01238679 still recruiting?

NCT01238679 is currently terminated. Last updated 24 December 2019.

Last reviewed 2019-12-24 · How we verify

NCT01238679

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PF-04958242 in Healthy Adult Volunteers

Terminated Phase 1 Last updated 24 December 2019

What this trial tests

Phase 1 trial testing PF-04958242 in Healthy Volunteers in 20 participants. Terminated before completion.

Timeline

24 November 2010

Primary endpoint
3 May 2011

3 May 2011

Quick facts

Lead sponsor	Biogen
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	20
Start date	24 November 2010
Primary completion	3 May 2011
Estimated completion	3 May 2011
Sites	1 location across Singapore

Drugs / interventions tested

PF-04958242 — full drug profile →
Placebo

Conditions studied

Healthy Volunteers — all drugs for Healthy Volunteers →

Sponsor

Biogen — full company profile →

Who can join

Adults 21 to 55, any sex, with Healthy Volunteers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this study evaluates the safety and tolerability of multiple, escalating doses of PF-04958242 administered orally to healthy adult participants.This study also evaluates the plasma and urine multiple dose pharmacokinetics (PK) of PF-04958242.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Positive AMPA receptor modulation in the treatment of neuropsychiatric disorders: A long and winding road.
Kadriu B, Musazzi L, Johnston JN, Kalynchuk LE, et al · · 2021 · cited 37× · PMID 34358693 · DOI 10.1016/j.drudis.2021.07.027

Verify or expand the search:

Other trials of PF-04958242

Trials testing the same drug.

NCT02855411 — A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizop · Phase 2 · terminated
NCT02341482 — A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of PF-04958242 in Healthy Subjects · Phase 1 · completed
NCT02332798 — Multiple Ascending Doses of PF-04958242 in Subjects With Stable Schizophrenia · Phase 1 · completed
NCT02228395 — Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-04958242 In Healthy Volunteers · Phase 1 · completed
NCT01365338 — A Study To Assess Effects Of PF-04958242 On Bold Functional Magnetic Resonance Imaging During Working Memory Activation · Phase 1 · completed

Other recruiting trials for Healthy Volunteers

Currently open trials in the same condition.

NCT07504003 — Influence of Training Session Duration on Improvements in Physiological Resilience to Exercise · NA · recruiting
NCT07446400 — A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuva · Phase 1 · recruiting
NCT07495813 — A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease · Phase 1 · recruiting
NCT07499050 — A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity · Phase 1 · recruiting
NCT07342114 — A Dose-Escalation Study of RO7875913 in Healthy Participants · Phase 1 · recruiting

Other Biogen trials

Trials by the same sponsor.

NCT07483632 — A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses · Phase 3 · not yet recruiting
NCT06628687 — A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants With Friedrich's Ataxia Who Took it Duri · recruiting
NCT07444450 — A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy · Phase 3 · not yet recruiting
NCT07444489 — A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants · Phase 3 · not yet recruiting
NCT07444476 — A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years Wit · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01238679 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Biogen
Last refreshed: 24 December 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01238679.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing